SPOTLIGHT -
Vancouver, British Columbia-An $855 million deal will unite verteporfin (Visudyne) developer QLT Inc. and Atrix Laboratories Inc. to build QLT's business and accelerate strategic initiatives.
SalioGen Therapeutics taps development candidate for ABCA4-mediated Stargardt disease
(EyePod) From idea to impact: Navigating ophthalmic innovation
Ocular Therapeutix announces positive topline Phase 1 data for Axpaxli in diabetic retinopathy
EyePod: Modifier Gene Therapy: What is it?
Patients with dry eye suffer from worse sleep quality
Ophthalmic industry veteran Erin Schallhorn Powers joins Holland Foundation for Sight Restoration Board of Directors